

Booking Date	26/09/2024	Patient ID : 012409260171	Reported on 08/10/2024
Name	Jyoti	Age : 62 Years	Sex - Female
Ref By	Dr. Amish Vora		

DIAGNOSIS: Her2 IHC 2+ (Equivocal) Breast Cancer IDC


METHODOLOGY: Fluorescence *in situ* Hybridization (FISH)

PROBE NAME: HEALTHCARE HER2/CEP17 dual color probe.

FISH:

Total number of cells scored	100
Total number of HER2 signals	1200
Total number of CEP17 signals	210
Average HER2 signals/cell	12.00
Computed Ratio	5.71

Positive



Cells showing HER2 signals (orange) and CEP17 signals (green).

CLINICAL INTERPRETATION:

1. Positive for HER2/neu amplification as per ASCO 2018 guidelines.
2. Her2:CEP17 ratio is ≥ 2 and Average Her2 signals ≥ 4 (Group 1).

RECOMMENDATION:

Please Note: Evaluation of this specimen shows abnormal hybridization pattern. These findings are indicative that the patient is eligible for anti HER2 therapy (Trastuzumab +/- Pertuzumab). Her2 gene amplification is seen 18 to 20% of invasive breast cancers. These tumours show increased over all survival rate with Her2 targeted therapy such as Trastuzumab +/- Pertuzumab. It has been recognized as a poor prognosis indicator in early breast cancer. In cases where tumor heterogeneity is present, analysis of HER2 FISH on additional blocks is recommended for conclusive result.